Variant · Snv

EGFR T790M

CI-VAR-00004341Explore in graph →NP_005219.2:p.Thr790MetNM_005228.4:c.2369C>TClinVar 16613 CIViC 34 rs121434569

Curated evidence

Evidence by cancer (61 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 51–61 of 61 evidence items across 5 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma5
EGFR T790M	Rociletinib	Predictive	B	Supports Sensitivity Response	4	accepted	EID646 In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC. PMID 25923550 · Sequist et al., 2015 · Open in CIViC	civic
EGFR T790M	Rociletinib	Predictive	B	Does Not Support Sensitivity Response	4	rejected	EID5709 Recently, the development of the third-generation epidermal growth factor receptor-small molecule inhibitor (EGFR-TKI) rociletinib had failed. in May 2016, after receiving a negative reply from the … (full text at CIViC) PMID 27785053 · Van Der Steen et al., 2016 · Open in CIViC	civic
EGFR T790M

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
16613	drug response	reviewed by expert panel	3	Tyrosine kinase inhibitor response; Non-small cell lung carcinoma; erlotinib response - Efficacy; EGFR-related lung cancer; Hereditary cancer-predisposing syndrome; gefitinib response - Efficacy; Lung cancer; Inflammatory skin and bowel disease, neonatal, 2; Lung adenocarcinoma; Neoplasm; EGFR-related disorder	germline/somatic	14

Malignant Lung Neoplasm3
EGFR L858R AND EGFR T790M	Nano TACs	Predictive	D	Supports Sensitivity Response	3	submitted	EID13326 NanoTACs are peptide-derived PROTAC nanoparticles designed to target wild-type EGFR and the EGFR L858R/T790M variant. Unlike conventional tyrosine kinase inhibitors (TKIs), which temporarily inhibit E… (full text at CIViC) PMID 41386736 · Jeong et al., 2026 · Open in CIViC	civic
EGFR T790M	Gefitinib + Multikinase Inhibitor AEE788Sequential	Predictive	D	Supports Resistance	5	accepted	EID642 Lung cancers can accumulate activating mutations in oncogenes such as EGFR. The common L858R EGFR mutation has been shown previously to be sensitive to small molecular tyrosine kinase inhibitors (ie. … (full text at CIViC) PMID 18227510 · Yun et al., 2008 · Open in CIViC	civic
EGFR T790M AND EGFR Exon 19 Deletion AND EGFR C797S	CH7233163	Predictive	D	Supports Sensitivity Response	3	submitted	EID13252 The novel tyrosine kinase inhibitor (TKI) CH7233163 has been reported to effectively overcome osimertinib resistance mediated by the EGFR Del19/T790M/C797S triple mutation. In vitro evaluation using e… (full text at CIViC) PMID 32943545 · Kashima et al., 2020 · Open in CIViC	civic